TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

PARTNER 3 update: TAVR still comparable to SAVR in low-risk patients after 7 years
PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025.
Medtronic launches FDA-cleared guidewire compatible with multiple TAVR systems
The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.
ASE leading push to revise CPT code for interventional echocardiography
The pressure is on for ASE and other societies to create a new CPT code for the use of interventional echocardiography during structural heart procedures.
Medtronic announces new AI partnership focused on improving TAVR care
Participating TAVR programs will receive AI-powered recommendations courtesy of DASI Simulations.
SGLT2 inhibitors after TAVR may boost survival, limit bioprosthetic valve dysfunction
Prescribing these drugs to TAVR patients could improve certain clinical outcomes, according to a new study of nearly 27,000 adults.

ICE guidance reduces risk of permanent pacemaker implantation after TAVR with a self-expandable valve

Heart teams can limit the risk of conduction disturbances that lead to permanent pacemaker implantation by utilizing both the cusp-overlap method and intracardiac echocardiography.

Valve-in-valve TAVR an effective tool for treating structural valve degeneration after SAVR

With heart teams performing valve-in-valve TAVR more and more, researchers wanted to take a fresh look at patient outcomes. Overall, they found, the procedure was linked to a low mortality rate and fewer permanent pacemakers than native-valve TAVR.

TAVR after mitral valve replacement linked to positive outcomes, but heart teams must plan ahead

Researchers in India performed TAVR on two relatively young patients with a preexisting mechanical mitral valve, sharing their experience in a new case report. The group highlighted the importance of planning ahead.

New expert guidelines: Start PHV evaluations with echocardiography, but other imaging modalities can provide value

New guidelines from the American Society of Echocardiography, made in collaboration with the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography, represent an update of the group's original recommendations from 2009.

Self-expanding TAVR system with new sealing cuff linked to high success rate, favorable outcomes

The valve, designed with a new-look sealing cuff for limiting paravalvular regurgitation, gained FDA approval in January 2023.

TAVR patients face a higher risk of stroke for up to 2 years

A majority of strokes after TAVR occur in the first 48 hours, but patients remain at a significantly higher risk for much longer.

Endocarditis after SAVR more likely with bovine valves

Researchers examined data from more than 21,000 patients treated from 1997 to 2018, publishing their findings in the Journal of the American Heart Association.

Acute kidney injury after TAVR linked to certain risks, but most patients have a full recovery

“These findings are highly pertinent in a clinical setting," researchers explained.

TAVR

PARTNER 3 update: TAVR still comparable to SAVR in low-risk patients after 7 years

Medtronic launches FDA-cleared guidewire compatible with multiple TAVR systems

ASE leading push to revise CPT code for interventional echocardiography

Medtronic announces new AI partnership focused on improving TAVR care

SGLT2 inhibitors after TAVR may boost survival, limit bioprosthetic valve dysfunction